Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

King International Investment Limited
帝王國際投資有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 928)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPLIANCE WITH RULES 3.10(1) AND 3.10A OF THE LISTING RULES

The board (the "**Board**") of directors (the "**Directors**") of King International Investment Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Zhou Yongchun (周永春) ("**Mr. Zhou**") has been appointed as an independent non-executive Director with effect from 5 November 2026.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The biographical details of Mr. Zhou are set out below:

Mr. Zhou Yongchun (周永春), aged 61, has extensive experience in the pharmaceutical and biotechnology industries, particularly in research and development and corporate management. He obtained a bachelor's degree in biochemical engineering from East China University of Science and Technology *(華東理工大學) in July 1986 and a master's degree from the same university in July 1989. He holds the professional title of senior engineer.

From July 1989 to March 2000, Mr. Zhou worked at the Second Military Medical University *(第二軍醫大學), where he held various academic positions, including teaching assistant, lecturer and associate professor.

From April 2000 to July 2002, Mr. Zhou served as the deputy general manager of Shanghai Clone High Technology Co., Ltd. *(上海克隆生物高技術有限公司). From August 2002 to December 2004, he served as the head of the Gene Medicine Research Centre of Shanghai Fosun Biomedical Research Institute Co., Ltd. *(上海復星生物醫藥研究院有限公司). He subsequently served as the general manager of Shanghai Clone High Technology Co., Ltd. from May 2005 to November 2008.

From November 2008 to June 2014, Mr. Zhou served as a director and general manager of Shanghai Chemo Biopharma Co., Ltd. *(上海凱茂生物醫藥有限公司).

From July 2014 to April 2025, Mr. Zhou served as the vice president and chief scientist of Jiangsu Wanbang Biopharmaceutical Co., Ltd. *(江蘇萬邦生化醫藥股份有限公司) and concurrently served as chairman of Shanghai Chemo Biopharma Co., Ltd. During this period, he also served as deputy dean of the research institute of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. *(上海復星醫藥(集團)股份有限公司) from January 2017 to December 2019 and chairman of Jiangsu Wanbang Pharmaceutical Technology Co., Ltd.*(江蘇萬邦醫藥科技有限公司) from January 2019 to April 2025.

Since June 2025, Mr. Zhou has served as a council member of the Shanghai Synthetic Biology Industry Association *(上海市合成生物產業協會).

As at the date of this announcement, Mr. Zhou does not (i) hold any other position in the Company and other members of the Group; (ii) hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) hold any other major appointments and professional qualifications, save as disclosed above.

As at the date of this announcement, Mr. Zhou has no relationships with any Director, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Under the letter of appointment entered into between Mr. Zhou and the Company, his term of service is one year. His directorship with the Company shall be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Mr. Zhou's remuneration is HK$10,000 per month, which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Mr. Zhou has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Zhou that need to be brought to the attention of the shareholders of the Company, and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Mr. Zhou for joining the Company.

COMPLIANCE WITH RULES 3.10(1) AND 3.10A OF THE LISTING RULES

Following the appointment of Mr. Zhou, the Company has three independent non-executive Directors. Accordingly, the Company is in compliance with Rules 3.10(1) and 3.10A of the Listing Rules.

By order of the Board
King International Investment Limited
Wang Mengyao
Executive Director

Hong Kong, 5 November 2026

As at the date of this announcement, the Board comprises:

Executive Directors:
Mr. Leng Yueyingtan *(Co-Chairman)*
Mr. Wang Jun *(Co-chairman)*
Mr. Wang Mengyao
Mr. Man Wai Lun
Mr. Li Li

Independent non-executive Directors:
Mr. Liu Zhong
Ms. Li Qian
Mr. Zhou Yongchun

* *For identification purposes only.*